Maartje van Seijen YOU? Author Swipe

Last 10y

Cause‐specific mortality after a diagnosis of ductal carcinoma in situ: Associations with screening and socio‐economic status Open

Renée Schmitz, Alexandra W. van den Belt‐Dusebout, Maartje van Seijen, Ellen Verschuur, Frederieke van Duijnhoven , et al. · 2025

The lower all‐cause mortality in women with Ductal carcinoma in situ (DCIS) compared with the general population has been hypothesized to be due to a “healthy‐user effect,” but this has not been studied in large cohorts. In a population‐ba…

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer Open

Rita A. Mukhtar, Soumya Gottipati, Christina Yau, Sara López‐Tarruella, Helena Earl , et al. · 2025

Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) is validated to predict event-free survival (EFS) in breast cancer but has not been studied for invasive lobular carcinoma (ILC). We studied patient-level data from a pooled…

Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade Open

Marte C. Liefaard, Anna van der Voort, Maartje van Seijen, Bram Thijssen, Joyce Sanders , et al. · 2024

The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population Open

Sena Alaeikhanehshir, Renée Schmitz, Alexandra W. van den Belt‐Dusebout, Frederieke van Duijnhoven, Ellen Verschuur , et al. · 2023

Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore Open

Tessa G. Steenbruggen, Maartje van Seijen, L. Janssen, Mette S. van Ramshorst, Erik van Werkhoven , et al. · 2023

Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore Open

Tessa G. Steenbruggen, Maartje van Seijen, L. Janssen, Mette S. van Ramshorst, Erik van Werkhoven , et al. · 2023

Purpose:In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant therapy improves recurrence-free survival of pa…

Supplementary Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore Open

Tessa G. Steenbruggen, Maartje van Seijen, L. Janssen, Mette S. van Ramshorst, Erik van Werkhoven , et al. · 2023

Supplementary data to Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MJTDF, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by R…

Supplementary Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore Open

Tessa G. Steenbruggen, Maartje van Seijen, L. Janssen, Mette S. van Ramshorst, Erik van Werkhoven , et al. · 2023

Supplementary data to Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MJTDF, et al. Prognostic value of residual disease after neoadjuvant therapy in HER2-positive breast cancer evaluated by R…

Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore Open

Tessa G. Steenbruggen, Maartje van Seijen, L. Janssen, Mette S. van Ramshorst, Erik van Werkhoven , et al. · 2023

Figure S1 from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore

Data from Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore Open

Tessa G. Steenbruggen, Maartje van Seijen, L. Janssen, Mette S. van Ramshorst, Erik van Werkhoven , et al. · 2023

Purpose:In breast cancer, pathologic complete response (pCR) to neoadjuvant systemic therapy (NST) is associated with favorable long-term outcome. Trastuzumab emtansine as additional adjuvant therapy improves recurrence-free survival of pa…

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance Open

Marlous Hoogstraat, Esther H. Lips, Isabel Mayayo‐Peralta, Lennart Mulder, Petra Kristel , et al. · 2022

Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast Open

Maartje van Seijen, Esther H. Lips, Liping Fu, Daniele Giardiello, Frederieke van Duijnhoven , et al. · 2021

Variability in grading of ductal carcinoma <i>in situ</i> among an international group of pathologists Open

Maartje van Seijen, Katarzyna Jóźwiak, Sarah E. Pinder, Allison Hall, Savitri Krishnamurthy , et al. · 2021

The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due to high interobserver variability and the use of multiple guidelines. The aim of this study was to evaluate interobserver agreement in grad…

Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study Open

Emma J. Groen, Jan Hudeček, Lennart Mulder, Maartje van Seijen, Mathilde M. Almekinders , et al. · 2020

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials Open

Jan Hudeček, Leonie Voorwerk, Maartje van Seijen, Iris Nederlof, Michiel de Maaker , et al. · 2020

The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review Open

Sena Alaeikhanehshir, Ellen G. Engelhardt, Frederieke van Duijnhoven, Maartje van Seijen, Patrick A. Bhairosing , et al. · 2020

Ductal carcinoma in situ: to treat or not to treat, that is the question Open

Maartje van Seijen, Esther H. Lips, Alastair M. Thompson, Serena Nik‐Zainal, P. Andrew Futreal , et al. · 2019

Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen Open

Maartje van Seijen, Luka Brčić, Atilio Navarro Gonzales, Irene Sansano, Mátyás Béndek , et al. · 2019

PO-069 Clinical and histological risk factors for subsequent in situ lesions after a primary diagnosis of ductal carcinoma in situ Open

Maartje van Seijen, Liping Fu, Ewout J. N. Groen, Lindy L. Visser, Lotte Elshof , et al. · 2018

Introduction Ductal carcinoma in situ (DCIS) is considered a potential precursor lesion of invasive breast cancer and is treated to prevent the development of invasive disease. After DCIS treatment, three scenarios emerge: i) the DCIS les…

Enrichment of high-grade tumors in breast cancer gene expression studies Open

Maartje van Seijen, Antien L. Mooyaart, Lennart Mulder, Marlous Hoogstraat, Caroline A. Drukker , et al. · 2017

Salivary gland infection with Candida tropicalis: antibiotic suppression therapy resulting in selection of uncommon pathogens Open

Joffrey van Prehn, Annette J. van Nieuwenhuizen, Stijn van Weert, Maartje van Seijen, Andries E. Budding · 2015

Introduction: Candida infection of the salivary glands is extremely rare, and a parotid gland infection with Candida tropicalis in an immunocompetent patient has, to the best of our knowledge, never been described before. Case presentation…

Fetching topic information...